STOCK TITAN

Erasca, Inc. - ERAS STOCK NEWS

Welcome to our dedicated page for Erasca news (Ticker: ERAS), a resource for investors and traders seeking the latest updates and insights on Erasca stock.

Erasca, Inc. (Nasdaq: ERAS) is a clinical-stage precision oncology company dedicated to discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Their mission, embodied in their name, is to 'erase cancer'. The company's innovative approach aims to not just treat but potentially cure cancer by targeting and shutting down the RAS/MAPK pathway, which plays a crucial role in many types of cancer.

Erasca’s robust clinical pipeline includes promising drug candidates such as Naporafenib, a pan-RAF inhibitor with first-in-class potential targeting NRASm melanoma and RAS Q61X tissue agnostic solid tumors. The company's other notable candidates include ERAS-007, a highly selective oral ERK1/2 inhibitor, and ERAS-601, an oral SHP2 inhibitor, which target different nodes of the RAS/MAPK pathway. These efforts are supported by recent collaborations with industry giants like Novartis, who are providing crucial compounds like trametinib (MEKINIST®) for combination trials.

On the financial front, Erasca is well-funded with significant investments from both new and existing investors, having recently raised approximately $45 million in a private placement expected to close in April 2024. As of December 2023, the company reported $322 million in cash, cash equivalents, and marketable securities, ensuring a solid runway into the second half of 2026.

Among their latest achievements, Erasca has received FDA Fast Track Designation (FTD) for Naporafenib in combination with trametinib for advanced NRASm melanoma. This designation facilitates accelerated development and review processes, reflecting the potential of their therapies to address unmet medical needs.

The company’s pivotal Phase 3 SEACRAFT-2 trial for Naporafenib in post-immunotherapy settings for NRASm melanoma is slated to begin in the first half of 2024. Additionally, Erasca has announced exciting new partnerships and pipeline enhancements, including in-licensing two preclinical RAS programs, ERAS-0015 and ERAS-4001, to further solidify their leadership in the precision oncology space.

For more up-to-date information on Erasca, Inc., including their latest financial results and key upcoming milestones, visit their official website or recent press releases.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.05%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.05%
Tags
-
Rhea-AI Summary
Erasca, Inc. will participate in a fireside chat and investor meetings at the Bank of America Securities 2023 Health Care Conference.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.55%
Tags
conferences
Rhea-AI Summary
Erasca's ERAS-801 receives Fast Track Designation from FDA for treatment of glioblastoma with EGFR gene alterations. ERAS-801 is an EGFR inhibitor with high CNS penetration and broad activity against oncogenic and wildtype EGFR. Phase 1 data expected in H2 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.17%
Tags
none
-
Rhea-AI Summary

Erasca, Inc. (Nasdaq: ERAS) has announced presentations at the American Society of Clinical Oncology (ASCO) Annual Meeting, scheduled for June 2-6, 2023, in Chicago. The posters will detail preliminary Phase 1b combination data for ERAS-007, a potential best-in-class ERK1/2 inhibitor, in patients with gastrointestinal malignancies. Key presentations include:

  • Abstract 3557: Data from ERAS-007 combined with encorafenib and cetuximab in patients with metastatic BRAF V600E mutated colorectal cancer.
  • Abstract 3558: Data from ERAS-007 combined with palbociclib in patients with KRAS/NRAS mutated colorectal cancer or KRAS mutated pancreatic ductal adenocarcinoma.

These studies reflect Erasca's commitment to advancing therapies targeting the RAS/MAPK pathway.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.56%
Tags
none
-
Rhea-AI Summary

Erasca, Inc. (ERAS) recently published preliminary results in the Journal of Clinical Oncology from a Phase 1b study assessing naporafenib and trametinib for NRAS-mutant melanoma. The study reported a promising 47% overall response rate (ORR) and a median progression-free survival (mPFS) of 5.5 months using a preferred dosing regimen. This combination is significant as NRAS mutations affect about 20% of melanoma patients, with no currently approved targeted therapies. Given its higher efficacy compared to standard chemotherapy, which shows an ORR of only 7% and mPFS of 1.5 months, Erasca plans to initiate a pivotal Phase 3 trial (SEACRAFT-2) in H1 2024. The study reinforces the potential of this combination therapy in improving outcomes for patients with NRASm melanoma.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.7%
Tags
Rhea-AI Summary

Erasca (Nasdaq: ERAS) announced promising initial results from the Phase 1b FLAGSHP-1 study for its SHP2 inhibitor ERAS-601 combined with cetuximab (ERBITUX) in patients with advanced solid tumors. The combination therapy showed favorable pharmacokinetics, with no significant drug-drug interactions and primarily low-grade adverse events (AEs). The maximum tolerated dose was established at 40 mg BID with a dosing schedule of three weeks on followed by one week off. The company plans to explore efficacy in HPV-negative head and neck squamous cell carcinoma (HNSCC), an area of high unmet medical need, with dose expansion data expected in the first half of 2024. The results support the potential of ERAS-601 as a backbone therapy, aiming to delay therapeutic resistance in cancer treatment.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.39%
Tags
-
Rhea-AI Summary

Erasca, Inc. (Nasdaq: ERAS) announced the promotions of Shannon R. Morris, M.D., Ph.D., to Chief Medical Officer and Chandra D. Lovejoy, M.S., to Chief Regulatory Affairs Officer, effective immediately. Morris succeeds Wei Lin, M.D., who is stepping down. Jonathan E. Lim, M.D., the chairman and CEO, praised both leaders for their integral roles in Erasca's clinical and regulatory achievements, especially with the recent in-licensing of naporafenib. Morris brings over 20 years of oncology experience, having led successful programs at Istari Oncology, G1 Therapeutics, and AstraZeneca. Lovejoy, with two decades in regulatory affairs, has also held pivotal roles in successful drug approvals. The company remains focused on advancing its RAS/MAPK pathway-driven therapies, positioning itself for growth.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.83%
Tags
none
-
Rhea-AI Summary

Erasca, a clinical-stage oncology company, announced significant developments in its recent press release. The company signed an exclusive worldwide license for naporafenib, a pan-RAF inhibitor, and completed a $100 million equity offering. It plans multiple clinical data readouts throughout 2023, including for its ERAS-007 and ERAS-601 therapies. As of December 31, 2022, Erasca had a robust balance sheet with cash and equivalents totaling $436 million, expected to support operations into H2 2025. However, the company reported a net loss of $242.8 million for the full year 2022, primarily due to in-process R&D expenses associated with the naporafenib licensing agreement.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.8%
Tags
Rhea-AI Summary

Erasca Inc. (Nasdaq: ERAS) announced a poster presentation at the AACR Annual Meeting on April 18, 2023, discussing preliminary Phase 1 dose escalation data for ERAS-601, a potential best-in-class SHP2 inhibitor, in combination with cetuximab. This study focuses on advanced or metastatic solid tumors. The poster will be available online post-presentation. The company emphasized its mission to develop therapies targeting RAS/MAPK pathway-driven cancers and highlighted the scientific expertise behind its cancer treatments. Caution is advised regarding forward-looking statements on product efficacy and potential risks in clinical development.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.45%
Tags
none

FAQ

What is the current stock price of Erasca (ERAS)?

The current stock price of Erasca (ERAS) is $2.865 as of November 4, 2024.

What is the market cap of Erasca (ERAS)?

The market cap of Erasca (ERAS) is approximately 795.2M.

What is Erasca, Inc.'s primary focus?

Erasca, Inc. is focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers.

What are the key drugs in Erasca’s pipeline?

Key drugs in Erasca's pipeline include Naporafenib, ERAS-007, and ERAS-601 targeting various nodes of the RAS/MAPK pathway.

What recent achievements has Erasca reported?

Erasca has received FDA Fast Track Designation for Naporafenib in combination with trametinib and announced significant collaborations and financial investments.

How is Erasca funded?

Erasca is funded through a combination of private placements and existing investments, with a strong cash position reported at $322 million as of December 2023.

What partnerships has Erasca entered into?

Erasca has partnered with Novartis, among others, to support clinical development of their drug candidates and has in-licensed two preclinical RAS programs.

What is the SEACRAFT-2 trial?

The SEACRAFT-2 trial is a pivotal Phase 3 study evaluating the efficacy of Naporafenib in combination with trametinib for NRAS-mutant melanoma patients post-immunotherapy.

What does FDA Fast Track Designation mean for Erasca?

FDA Fast Track Designation facilitates accelerated development and review processes for Naporafenib in combination with trametinib, aiming to expedite its availability for patients with advanced NRAS-melanoma.

What financial milestones has Erasca achieved recently?

Recently, Erasca secured approximately $45 million in a private placement and reported a strong cash position to fund operations into 2026.

What is the significance of Erasca's mission statement?

Erasca's mission to 'erase cancer' reflects their dedication to creating transformative oncology therapies aimed at not just treating but potentially curing cancer.

How does Erasca's technology target cancer?

Erasca's technology targets the RAS/MAPK pathway, which is critical in many cancers. Their therapies aim to comprehensively shut down this pathway to treat and potentially cure cancer.

Erasca, Inc.

Nasdaq:ERAS

ERAS Rankings

ERAS Stock Data

795.25M
282.50M
12.4%
77.06%
11.93%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
SAN DIEGO